Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors

Several recent cardiovascular trials of SGLT 2 (sodium-glucose cotransporter 2) inhibitors revealed that they could reduce adverse cardiovascular events in patients with T2DM (type 2 diabetes mellitus). However, the exact molecular mechanism underlying the beneficial effects that SGLT2 inhibitors ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabravolski, Siarhei A., Zhuravlev, Alexander D., Kartuesov, Andrey G., Borisov, Evgeny E., Sukhorukov, Vasily N., Orekhov, Alexander N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140946/
https://www.ncbi.nlm.nih.gov/pubmed/35628174
http://dx.doi.org/10.3390/ijms23105371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140946/
https://www.ncbi.nlm.nih.gov/pubmed/35628174
http://dx.doi.org/10.3390/ijms23105371

Ejemplares similares